Argenx Profit Misses Estimates Following Large Acquisition
Biotech operators should note how high integration costs can impact quarterly margins despite significant growth in product sales.
Updated on Oct. 22, 2026 in Healthcare
Live Poll
Do you trust pharmaceutical companies that prioritize large acquisitions over maintaining stable operating margins?
Argenx reported Q3 2026 Vyvgart sales of $1.7 billion, representing a 54% increase over the same period last year. However, the company posted an operating profit of $486 million, missing analyst expectations due to costs associated with its $2.2 billion acquisition of Forte Biosciences.
Why it matters
The company's operating margin fell to 28.2% as integration expenses from its recent acquisition weighed on short-term profitability. This shift highlights how aggressive M&A strategies and high research and commercialization costs can temporarily squeeze bottom-line margins despite strong core product growth.
Vyvgart sales reached $1.7 billion in Q3 2026, up 54% from $1.13 billion in Q3 2025. While sales grew, the company reported an operating profit of $486 million, falling short of the $565.82 million consensus estimate as operating margins contracted to 28.2%.
The players
Argenx
A biotechnology company headquartered in Belgium and the Netherlands focused on developing antibody-based therapies for severe autoimmune diseases.
Forte Biosciences
A clinical-stage biopharmaceutical company focused on dermatology and immunology that was acquired by Argenx.
The details
The revenue growth was driven by an expansion in the total number of patients receiving Vyvgart treatment. Conversely, the profit miss stems from the $2.2 billion acquisition of Forte Biosciences completed in August 2026. The firm is now absorbing these acquisition costs alongside its existing pipeline expenses, which are projected to reach $4 billion in total operating costs for 2026.
Timeline
August 2026: Argenx completed the acquisition of Forte Biosciences.
Q3 2026: Vyvgart sales reached $1.7 billion.
Full Year 2026: Total R&D and SG&A costs are projected to reach $4 billion.
Market Landscape
The company's recent financials align with the broader industry trend of prioritizing patient acquisition through intensive R&D and strategic M&A. This activity follows the projected $4 billion annual cost baseline, signaling a commitment to long-term growth despite immediate margin pressure.
Operators in the biotechnology sector should monitor how the company balances its $4 billion projected operating cost load against rising therapy adoption. Keeping a close watch on margin recovery trends is essential for assessing the efficacy of recent integration strategies.
The takeaway
Rapid market expansion often requires significant upfront investment that can temporarily mask core product success. Operators should track the relationship between R&D spending and operating margins to determine if acquisition-driven growth is sustainable over the next fiscal cycle.
Further reading
For broader trends in industry performance, see the latest updates in Healthcare.
Live Poll
Do you trust pharmaceutical companies that prioritize large acquisitions over maintaining stable operating margins?
